BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability
Open Access
- 9 October 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 27 (3), 629-634
- https://doi.org/10.1038/leu.2012.294
Abstract
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia in chronic phase (CML-CP). Unfortunately, 25% of TKI-naive patients and 50–90% of patients developing TKI-resistance carry CML clones expressing TKI-resistant BCR-ABL1 kinase mutants. We reported that CML-CP leukemia stem and progenitor cell populations accumulate high amounts of reactive oxygen species, which may result in accumulation of uracil derivatives in genomic DNA. Unfaithful and/or inefficient repair of these lesions generates TKI-resistant point mutations in BCR-ABL1 kinase. Using an array of specific substrates and inhibitors/blocking antibodies we found that uracil DNA glycosylase UNG2 were inhibited in BCR-ABL1-transformed cell lines and CD34+ CML cells. The inhibitory effect was not accompanied by downregulation of nuclear expression and/or chromatin association of UNG2. The effect was BCR-ABL1 kinase-specific because several other fusion tyrosine kinases did not reduce UNG2 activity. Using UNG2-specific inhibitor UGI, we found that reduction of UNG2 activity increased the number of uracil derivatives in genomic DNA detected by modified comet assay and facilitated accumulation of ouabain-resistant point mutations in reporter gene Na+/K+ATPase. In conclusion, we postulate that BCR-ABL1 kinase-mediated inhibition of UNG2 contributes to accumulation of point mutations responsible for TKI resistance causing the disease relapse, and perhaps also other point mutations facilitating malignant progression of CML.Keywords
This publication has 53 references indexed in Scilit:
- Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitorsBlood, 2012
- BCR-ABL1 Kinase: Hunting an Elusive Target with New WeaponsCell Chemical Biology, 2011
- The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance ProfileCancer Research, 2011
- BCR/ABL Stimulates WRN to Promote Survival and Genomic InstabilityCancer Research, 2011
- Incorporation of dUTP does not mediate mutation of A:T base pairs in Ig genes in vivoNucleic Acids Research, 2010
- Chronic myeloid leukemia: mechanisms of blastic transformationJCI Insight, 2010
- Uracil in DNA and its processing by different DNA glycosylasesPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2008
- Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to ImatinibMolecular and Cellular Biology, 2006
- Nucleotide excision repair DNA synthesis by excess DNA polymerase β: a potential source of genetic instability in cancer cellsThe FASEB Journal, 2000
- Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase βOncogene, 1999